Title : Development of a vegf-loaded phytosolve s75 for thin endometrium therapy
Abstract:
Thin endometrium, characterized by insufficient vascularization due to reduced vascular endothelial growth factor (VEGF), is a major cause of implantation failure and infertility. Inducing angiogenesis through targeted VEGF delivery presents a promising therapeutic strategy. This study aimed to develop an advanced drug delivery system using S75 lipoid-based PhytoSolve to enhance VEGF stability and bioavailability for thin endometrium therapy.
The PhytoSolve formulation, composed of S75 lipoid, glycerol, and MCT oil, was synthesized using a probe sonicator to achieve a nanoemulsion with an average particle size of 67.57±7.07 nm. To evaluate its therapeutic potential, a thin endometrial model was induced in female NMRI mice via 95% ethanol injection, and animals were divided into six groups: control, sham, thin endometrial model, VEGF treatment, PhytoSolve treatment, and VEGF/PhytoSolve treatment.
VEGF release from the PhytoSolve formulation followed a controlled pattern, with 40% released within the first 24 hours, followed by a sustained 10–20% daily release. Histological analysis revealed a significant increase in endometrial thickness in the VEGF/PhytoSolve group compared to VEGF alone (P<0.05), indicating superior angiogenesis and tissue regeneration.
These findings highlight the potential of PhytoSolve S75 as a novel, biocompatible nano-drug delivery system for enhancing VEGF-based therapies. This approach not only provides a sustained release system for VEGF but also offers a promising therapeutic strategy for treating thin endometrium and potentially other vascular-related disorders in biomedical application
